Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Merrimack Pharma employee arrested on U.S. insider trading charge

Published 02/07/2017, 06:21 PM
© Reuters.  Merrimack Pharma employee arrested on U.S. insider trading charge

By Nate Raymond

(Reuters) - A Merrimack Pharmaceuticals Inc (O:MACK) employee was arrested on Tuesday on charges that he engaged in an insider trading scheme with a former employee of a rival biopharmaceutical company.

Songjiang Wang, who Cambridge, Massachusetts-based Merrimack has employed as director of statistical programming since 2011, was charged with conspiring to commit securities fraud in a criminal complaint filed in federal court in Boston.

He was arrested after prosecutors brought related charges in June against Schultz Chan, who had been the director of biostatistics at another Cambridge-based company, Akebia Therapeutics Inc (O:AKBA).

Wang, 52, of Westford, Massachusetts, was released on a $750,000 bond after a court hearing on Tuesday, a spokeswoman for Acting U.S. Attorney William Weinreb in Boston said.

Wang's lawyer did not respond to a request for comment. A lawyer for Chan, who has pleaded not guilty, declined to comment.

Merrimack said in a statement that the case was an "isolated matter involving a single, non-executive level employee" and the company was cooperating with authorities.

In separate statement issued later on Tuesday, Merrimack said Wang was no longer an employee of the company.

"Merrimack takes seriously compliance and is committed to the highest standards of ethical conduct as we work to develop treatments for cancer patients around the world," the statement said.

According to the complaint, Wang provided Chan inside information in 2013 and 2014, ahead of announcements by Merrimack about positive results in three different drug studies. This allowed Chan to place trades based on those tips.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Chan, in turn, tipped Wang in advance of positive clinical study results for a new drug being developed by Akebia, which allowed him to place trades ahead of the company's announcement in September 2015, the complaint said.

Based on that tip, Wang made $105,000 in illegal trading profits, according to an earlier lawsuit against Chan by the U.S. Securities and Exchange Commission.

That lawsuit referred to Wang, without using his name, as friend of Chan's who had previously loaned him $80,000.

The case is U.S. v. Wang, U.S. District Court, District of Massachusetts, No. 17-mj-1005.

Latest comments

I am not surprised. It took them long enough.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.